Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity.

Abstract

Azinomycins A and B, isolated from the culture broth of Streptomyces griseofuscus S 42227, were examined for antitumor activities against P388 leukemia, P815 mastocytoma, B-16 melanoma, Ehrlich carcinoma, Lewis lung carcinoma and Meth A fibrosarcoma. Azinomycin B was markedly effective against the intraperitoneally inoculated tumors such as P388 leukemia, B-16 melanoma and Ehrlich carcinoma. The intraperitoneal administration of azinomycin B showed 57% survivors for 45 days and 193% ILS against P388 leukemia. For Ehrlich carcinoma, azinomycin B gave 161% ILS and 63% survivors for 45 days, but solid tumors such as Lewis lung carcinoma and Meth A fibrosarcoma were not susceptible to repeated injection of this substance. Azinomycin A was somewhat less effective than azinomycin B for the tumor systems tested.

• Authors: S Ishizeki, M Ohtsuka, K Irinoda, K Kukita, K Nagaoka, T Nakashima
• Journal: The Journal of antibiotics (J Antibiot (Tokyo)) Vol. 40 Issue 1 Pg. 60-5 (Jan 1987) ISSN: 0021-8820 [Print] England
• PMID: 3104267 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Antibiotics, Antineoplastic
• Azabicyclo Compounds
• Dipeptides
• Glycopeptides
• Intercellular Signaling Peptides and Proteins
• Mitomycins
• Naphthalenes
• Peptides
• azinomycin B
• azinomycin A
• Mitomycin

Topics

• Animals
• Anti-Bacterial Agents
• Antibiotics, Antineoplastic (therapeutic use)
• Azabicyclo Compounds
• Carcinoma, Ehrlich Tumor (drug therapy)
• Dipeptides
• Drug Evaluation, Preclinical
• Fibrosarcoma (drug therapy)
• Glycopeptides (therapeutic use)
• Intercellular Signaling Peptides and Proteins
• Leukemia P388 (drug therapy)
• Lung Neoplasms (drug therapy)
• Mast-Cell Sarcoma (drug therapy)
• Melanoma, Experimental (drug therapy)
• Mice
• Mitomycin
• Mitomycins (therapeutic use)
• Naphthalenes
• Neoplasms, Experimental (drug therapy)
• Peptides
• Structure-Activity Relationship